Sol-Gel Technologies (SLGL) Receivables - Net (2019 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Receivables - Net of $2.0 million for Q4 2025, down 45.26% year-over-year from $3.6 million in Q4 2024, and down 80.4% quarter-over-quarter from $10.0 million in Q2 2025.
Sol-Gel Technologies (SLGL) Receivables - Net (2019 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Receivables - Net for 7 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net fell 45.26% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (down 45.26% YoY), while the FY2025 annual figure was $2.0 million, down 45.26% from the prior year.
- Receivables - Net retreated to $2.0 million in Q4 2025 per SLGL's latest filing, from $10.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $13.1 million in Q4 2021 and bottomed at $377000.0 in Q4 2023.
- Historically, Receivables - Net has averaged $5.6 million across 5 years, with a median of $5.8 million in 2023.
- Annual changes were most pronounced in 2022 — Receivables - Net soared 1268.27% — and 2023, when it slumped 95.2%.
- Sol-Gel Technologies' Receivables - Net stood at $13.1 million in 2021, then tumbled by 39.85% to $7.9 million in 2022, then plunged by 95.2% to $377000.0 in 2023, then jumped by 853.58% to $3.6 million in 2024, then slumped by 45.26% to $2.0 million in 2025.
- Business Quant data shows SLGL's Receivables - Net at $2.0 million in Q4 2025, $10.0 million in Q2 2025, and $3.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.97 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Dec 31, 2023 | 377,000.00 |
| Dec 31, 2023 | 377,000.00 |
| Jun 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Sep 30, 2022 | 10.78 Mn |
| Sep 30, 2022 | 10.78 Mn |
| Jun 30, 2022 | 10.18 Mn |
| Jun 30, 2022 | 10.18 Mn |